MTOR and melanoma: FKBP51s marks a subset of Tregs, which, according to increased p-mTOR levels,17 is expected to exert an effective suppressive activity.29 Herein, investigating a different cohort of melanoma patients, we confirm previous findings17 that this Treg subset is associated with response to checkpoint-targeted therapy.